Publication Date: 10 Feb 2011
Type: Review
Journal: Clinical Medicine Insights: Therapeutics
Citation: Clinical Medicine Insights: Therapeutics 2011:3 81-92
doi: 10.4137/CMT.S6227
Type 2 diabetes mellitus (T2DM) has become an epidemic, with worldwide projections indicating that more than 336 million people will be afflicted with the disease by 2030. T2DM is characterized by inappropriately high blood glucose levels due to a deficiency in insulin secretion, action, or both. Despite the horrific complications that occur with chronic elevations of blood glucose levels, less than half of those with T2DM do not maintain proper glycemic control. Sitagliptin (Januvia, Merck and Co., Whitehouse Station, New Jersey) is a novel diabetes therapy approved for use in the U.S. and Europe. This small molecule inhibits the activity of DPP-4, a peptidase that degrades the glucoregulatory hormone GLP-1. Sitagliptin increases glucoregulation in individuals with T2DM both as a monotherapy and in combination with other antihyperglycemic drugs, with a low risk of adverse side effects.
PDF (549.78 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I was delighted to submit an invited review on cluster headache pharmacology. As someone who writes a few papers per year on these subjects, I appreciated that the submission, review and approval process for the paper was smooth and efficient. Our reviewers raised important points that improved the overall quality of the manuscript. Overall a very positive experience.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
Facebook Google+ Twitter
Pinterest Tumblr YouTube